These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 21117980)

  • 1. The natural history of malignancies under conditions of BRAF inhibitor stimulation.
    White RM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):135-6. PubMed ID: 21117980
    [No Abstract]   [Full Text] [Related]  

  • 2. The BRAF Inhibitor Vemurafenib Enhances UV-Induced Skin Carcinogenesis in Beta HPV38 E6 and E7 Transgenic Mice.
    Viarisio D; Müller-Decker K; Hassel JC; Alvarez JC; Flechtenmacher C; Pawlita M; Gissmann L; Tommasino M
    J Invest Dermatol; 2017 Jan; 137(1):261-264. PubMed ID: 27650607
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Don't miss the base - keratoacanthoma-type squamous cell carcinoma with perineural invasion during BRAF inhibitor therapy for melanoma.
    Schüürmann M; Pönitzsch I; Simon JC; Ziemer M
    J Dtsch Dermatol Ges; 2015 Dec; 13(12):1279-81. PubMed ID: 26612802
    [No Abstract]   [Full Text] [Related]  

  • 6. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V; Chevreau C
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract]   [Full Text] [Related]  

  • 7. The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
    Davis MJ; Schlessinger J
    J Cell Biol; 2012 Oct; 199(1):15-9. PubMed ID: 23027900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spindle cell squamous cell carcinoma arising from verrucous hyperplasia during BRAF inhibitor therapy for melanoma.
    Ziemer M; Pönitzsch I; Simon JC; Schüürmann M
    J Dtsch Dermatol Ges; 2015 Apr; 13(4):326-8. PubMed ID: 25761417
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma.
    Fathi R; Kamalpour L; Gammon B; Tung R
    Dermatol Surg; 2013 Feb; 39(2):341-4. PubMed ID: 23227856
    [No Abstract]   [Full Text] [Related]  

  • 10. [BRAF: the pathologist's favorite oncogene].
    Sabourin JC
    Ann Pathol; 2013 Dec; 33(6):373-4. PubMed ID: 24331718
    [No Abstract]   [Full Text] [Related]  

  • 11. [BRAF mutation detection in metastatic melanoma].
    Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract]   [Full Text] [Related]  

  • 12. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
    Bahadoran P; Allegra M; Le Duff F; Long-Mira E; Hofman P; Giacchero D; Passeron T; Lacour JP; Ballotti R
    J Clin Oncol; 2013 Jul; 31(19):e324-6. PubMed ID: 23715574
    [No Abstract]   [Full Text] [Related]  

  • 13. BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.
    Mesko SM; Rosenthal KJ; Boasberg PD; Hamid O
    J Clin Oncol; 2015 Sep; 33(25):e101-3. PubMed ID: 24711550
    [No Abstract]   [Full Text] [Related]  

  • 14. Aflibercept, ipilimumab, and vemurafenib.
    Hussar DA; Au AY
    J Am Pharm Assoc (2003); 2012; 52(2):291-4. PubMed ID: 22370387
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncogenic RAF: a brief history of time.
    Solit D; Rosen N
    Pigment Cell Melanoma Res; 2010 Dec; 23(6):760-2. PubMed ID: 20973931
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions.
    Ali M; Anforth R; Senetiner F; Carlos G; Fernandez-Penas P
    Exp Dermatol; 2016 May; 25(5):394-5. PubMed ID: 26896751
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
    Vigarios E; Lamant L; Delord JP; Fricain JC; Chevreau C; Barrés B; Gomez-Roca C; Boulanger M; Sibaud V
    Br J Dermatol; 2015 Jun; 172(6):1680-1682. PubMed ID: 25495246
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
    Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
    J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
    [No Abstract]   [Full Text] [Related]  

  • 20. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.